Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study
Abstract Background Multiple clinical trials demonstrate consistent but modest benefit of adjuvant extended endocrine therapy (EET) in HR + breast cancer patients. Predictive biomarkers to identify patients that benefit from EET are critical to balance modest reductions in risk against potential sid...
Main Authors: | Dennis C. Sgroi, Kai Treuner, Yi Zhang, Tammy Piper, Ranelle Salunga, Ikhlaaq Ahmed, Lucy Doos, Sarah Thornber, Karen J. Taylor, Elena Brachtel, Sarah Pirrie, Catherine A. Schnabel, Daniel Rea, John M. S. Bartlett |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-12-01
|
Series: | Breast Cancer Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13058-022-01589-x |
Similar Items
-
Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer
by: Rea, D, et al.
Published: (2013) -
AR/ER Ratio Correlates with Expression of Proliferation Markers and with Distinct Subset of Breast Tumors
by: Nelson Rangel, et al.
Published: (2020-04-01) -
Re-Expression of ERα and AR in Receptor Negative Endocrine Cancers via GSK3 Inhibition
by: Vikas Sharma, et al.
Published: (2022-03-01) -
Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer
by: Ho Tsoi, et al.
Published: (2022-01-01) -
AR Signaling in Breast Cancer
by: Bilal Rahim, et al.
Published: (2017-02-01)